^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

    Excerpt:
    Recommendations...First line treatment...In selected cases of HER2-positive, HR-positive breast cancer where the patient is not suitable for first-line ChT, ET (e.g. an AI) in combination with a HER2-targeted therapy such as trastuzumab, trastuzumab/pertuzumab, trastuzumab/lapatinib or lapatinib...
    Secondary therapy:
    Aromatase inhibitor
    DOI:
    https://doi.org/10.1016/j.annonc.2021.09.019.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Positive Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY FOR ER - AND/OR PR - POSITIVE RECURRENT OR STAGE IV (M1) DISEASE…HER2-Positive and Postmenopausal Receiving Ovarian Ablation or Suppression…Aromatase inhibitor ± lapatinib + trastuzumab...
    Secondary therapy:
    Aromatase inhibitor